Soft tissue sarcomas (STSs) represent a diverse group of tumors that pose significant diagnostic and therapeutic challenges. In a recent review published in the KeAi journal Meta-Radiology, a team of ...

For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a global team of researchers ...

Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma Over three-fold increase in tumour ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to radiation and surgery reduced relapse risk by 43%. Results showed no ...

Investigators developed the largest collection of sarcoma patient-derived organoids to date that can help improve the understanding of the disease and better identify therapies that are most likely to ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

In a retrospective analysis, moderately hypofractionated definitive radiotherapy (MHDRT) achieved 1-year local control rates of more than 90% for soft tissue sarcomas (STS) and 100% for chordomas in ...